

RUBRA MEDICAMENTS LIMITED

Statement of Standalone Unaudited Financial Results for the quarter ended June 30, 2021

(Rs. in Lakhs)

Sr.No.	Particulars	Figures for 3 months ended	Figures for preceeding 3 months ended	Figures for corresponding 3 months ended in the previous year	Figures for the previous year ended
		30-Jun-2021	31-Mar-2021	30-Jun-2020	31-Mar-2021
		Unaudited	Unaudited	Unaudited	Audited
I	Revenue from Operations	69.61	29.75	0.00	48.50
II	Other Income	0.00	0.00	0.00	0.00
III	Total Income (I + II)	69.61	29.75	0.00	48.50
IV	Expenses:				
	Cost of Materials Consumed	0.00	0.00	0.00	0.00
	Purchases of Stock in Trade	50.07	8.26	0.00	8.26
	Changes in Inventories of finished goods, work-in-progress and stock in trade	0.00	0.00	0.00	0.00
	Employee benefits Expense	0.77	16.45	0.60	19.54
	Finance Costs	0.01	0.03	0.00	0.04
	Depreciation & amortisation expense	0.04	0.04	0.00	0.16
	Other Expenses	17.81	4.27	0.00	19.68
	Total Expenses (IV)	68.70	29.05	0.60	47.68
V	Profit / (loss) before exceptional items and tax (III-IV)	0.91	0.70	-0.60	0.82
VI	Exceptional Items	0.00	0.00	0.00	0.00
VII	Profit / (loss) before tax (V-VI)	0.91	0.70	-0.60	0.82
VIII	Tax Expense:				
	(1) Current tax	0.20	0.25	0.00	0.25
	(2) Deferred tax	0.00	0.00	0.00	0.00
IX	Profit (Loss) for the period from continuing operations (VII-VIII)	0.71	0.45	-0.60	0.57
X	Profit/(loss) from discontinuing operations	0.00	0.00	0.00	0.00
XI	Tax Expense of discontinuing operations	0.00	0.00	0.00	0.00
XII	Profit/(loss) from Discontinuing operations (after tax)(X-XI)	0.00	0.00	0.00	0.00
XIII	Profit / (Loss) for the period (IX+XII)	0.71	0.45	-0.60	0.57
XIV	Other comprehensive income A (i) Items that will not be reclassified to profit or loss (ii) Income tax relating to items that will not be reclassified to profit or loss B (i) Items that will be reclassified to profit or loss (ii) Income tax relating to items that will be reclassified to profit or loss	0.00	0.00	0.00	0.00
XV	Total comprehensive income for the period (XIII+XIV)(Comprising Profit (Loss) and Other Comprehensive Income for the period)	0.71	0.45	-0.60	0.57
XVI	Earnings per equity share (for continuing operation): (1) Basic (2) Diluted	0.01 0.01	0.01 0.01	0.00 0.00	0.01 0.01
XVII	Earnings per equity share (for discontinued operation): (1) Basic (2) Diluted	0.00 0.00	0.00 0.00	0.00 0.00	0.00 0.00
XVIII	Earnings per equity share (for discontinued & continuing operation): (1) Basic (2) Diluted	0.01 0.01	0.01 0.01	0.00 0.00	0.01 0.01
	NOTES:				
1	The above Results have been reviewed by the Audit Committee and taken on Record by the Board of Directors at its meeting held today.				
2	The result is provisional and unaudited and subject to change, regrouping and restatement.				

For Rubra Medicaments Limited

Place: Mumbai
Date:- August 13, 2021

Abha Kapoor
Director (Finance) & CFO
DIN: 02799429